Drug Trial Radar · NCT07919015
Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Feb 1, 2026
Primary completion
Jun 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Avraham UntermanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Rambam Health Care Campus; Barzilai University Medical Center; The Chaim Sheba Medical Center
- First posted
- Nov 5, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Nerandomilast is an oral medicine that slows down the loss of functional residual capacity (FVC) in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It was tested in two large clinical trials in which participants were carefully selected. In everyday practice, patients are often older, have more other illnesses, or take additional medicines, and it is not known whether the benefits seen in the trials also occur outside them. The Real-world Study of Nerandomilast (ReaSoN-IPF/PPF) follows people with IPF or PPF who begin nerandomilast as part of their usual medical care at several medical centers in Israel. The study does not assign any treatment; the treating physician makes every decision about therapy. The main goal is to find out whether lung function declines more slowly once nerandomilast is started. Because patients have breathing tests before they begin the medicine as well as during treatment, each patient is compared with themselves: the rate at which their FVC was declining beforehand is compared with the rate following treatment. The study also asks how patients feel, using a questionnaire called the K-BILD, and records side effects, hospital admissions, disease exacerbations, and whether patients stop the medicine. Participants attend their normal clinic visits. They complete the questionnaire before treatment starts and again at 6 to 12 months, and their routine lung function results are collected. No extra tests or visits are required beyond the questionnaire.
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Progressive Pulmonary Fibrosis
Interventions
NerandomilastDrug
Either Nerandomilast 9mg twice a day or 18mg twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Through study completion, an average of 9 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Barzilai Medical Center, Ben-Gurion University of the Negev
Ashkelon, Israel · Recruiting
Rambam Health Care Campus, Technion - Israel Institute of Technology
Haifa, Israel · Recruiting
Sheba Medical Center, Tel-HaShomer, Tel-Aviv University
Ramat Gan, Israel · Recruiting
Tel-Aviv Sourasky University Medical Center, Tel-Aviv University
Tel Aviv, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.